The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in cyp2a6: The influence of genetics, race, and sex

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 4, 2013, Pages 708-718

  Zhu, Andy Z X ^a   Renner, Caroline C ^b   Hatsukami, Dorothy K ^c   Swan, Gary E ^d   Lerman, Caryn ^e   Benowitz, Neal L ^f   Tyndale, Rachel F ^a,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b ALASKA NATIVE MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d SRI INTERNATIONAL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; COTININE; CYTOCHROME P450 2A6; NICOTINE; NITROSAMINE;

ARTICLE; BLOOD LEVEL; CLEARANCE; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RACE; SEX DIFFERENCE; SMOKING; URINALYSIS;

AFRICAN AMERICANS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL MARKERS; CARCINOGENS; COTININE; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; PROGNOSIS; SEX FACTORS; SMOKING; TWIN STUDIES AS TOPIC;

EID: 84876565867     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1234-T     Document Type: Article

References (50)

1. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996;24:1212-7. (Pubitemid 26423061)
2. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Characterization of CYP2A6 involved in 30-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996;277: 1010-5.
3. Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P. Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. Nicotine Tob Res 2011;13: 772-83.
4. Boffetta P, Clark S, Shen M, Gislefoss R, Peto R, Andersen A. Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:1184-8.
5. Munafo MR, Timofeeva MN, Morris RW, Prieto-Merino D, Sattar N, Brennan P, et al. Association between genetic variants on chromosome15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst 2012;104:740-8.
6. Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 2011;103:1342-6.
7. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004;14:615-26. (Pubitemid 39281816)
8. Strasser AA, Benowitz NL, Pinto AG, Tang KZ, Hecht SS, Carmella SG, et al. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev 2011; 20:234-8.
9. Ho MK, Faseru B, Choi WS, Nollen NL, Mayo MS, Thomas JL, et al. Utility and relationships of biomarkers of smoking in African-American light smokers. Cancer Epidemiol Biomarkers Prev 2009;18: 3426-34.
10. Timofeeva MN, McKay JD, Smith GD, Johansson M, Byrnes GB, Chabrier A, et al. Genetic polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. Cancer Epidemiol Biomarkers Prev 2011;20:2250-61.
11. Zhu AZ, Binnington MJ, Renner CC, Lanier AP, Hatsukami DK, Stepanov I, et al. Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco specific nitrosamine exposure and lower tobacco specific nitrosamine bioactivation. Carcinogenesis 2013;34:93-101.
12. Gan WQ, Cohen SB, Man SF, Sin DD. Sex-related differences in serum cotinine concentrations in daily cigarette smokers. Nicotine Tob Res 2008;10:1293-300.
13. Al Koudsi N, Hoffmann EB, Assadzadeh A, Tyndale RF. Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. Eur J Clin Pharmacol 2010;66:239-51.
14. Wagenknecht LE, Cutter GR, Haley NJ, Sidney S, Manolio TA, Hughes GH, et al. Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. Am J Public Health 1990;80:1053-6. (Pubitemid 20261378)
15. Perez-Stable EJ, Herrera B, Jacob P III, Benowitz NL. Nicotine metabolism and intake in black and white smokers. JAMA 1998;280:152-6. (Pubitemid 28498387)
16. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev 1996;18:188-204. (Pubitemid 27082089)
17. Oscarson M, McLellan RA, Asp V, Ledesma M, Bernal Ruiz ML, Sinues B, et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6-12) that causes reduced CYP2A6 activity. Hum Mutat 2002;20:275-83.
18. Mwenifumbo JC, Tyndale RF. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 2007;8: 1385-402. (Pubitemid 350162852)
19. Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, et al. A novel polymorphism of human CYP2A6 gene CYP2A6-17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 2004;76:519-27. (Pubitemid 39601542)
20. Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 2008;29:679-88. (Pubitemid 351614592)
21. Benowitz NL, Swan GE, Jacob P III, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 2006;80:457-67. (Pubitemid 44767882)
22. Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF. A novel CYP2A6 allele, CYP2A6-23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics 2008;18:67-75. (Pubitemid 351161649)
23. Xu C, Rao YS, Xu B, Hoffmann E, Jones J, Sellers EM, et al. An in vivo pilot study characterizing the new CYP2A6-7, 8, and 10 alleles. Biochem Biophys Res Commun 2002;290:318-24. (Pubitemid 34694502)
24. Dempsey D, Tutka P, Jacob P III, Allen F, Schoedel K, Tyndale RF, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004;76:64-72. (Pubitemid 38844735)
25. Wang J, Liang Q, Mendes P, Sarkar M. Is 24h nicotine equivalents a surrogate for smoke exposure based on its relationship with other biomarkers of exposure? Biomarkers 2011;16:144-54.
26. Yuan JM, Gao YT, Murphy SE, Carmella SG, Wang R, Zhong Y, et al. Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Res 2011;71:6749-57.
27. St Helen G, Goniewicz ML, Dempsey D, Wilson M, Jacob P III, Benowitz NL. Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers. Chem Res Toxicol 2012;25: 952-64.
28. Benowitz NL, Renner C, Lanier A, Tyndale RF, Hatsukami DK, Lindgren BR, et al. Exposure to nicotine and carcinogens among Southwestern Alaskan native cigarette smokers and smokeless tobacco user. Cancer Epidemiol Biomarkers Prev 2012;21:934-42.
29. Swan GE, Benowitz NL, Lessov CN, Jacob P III, Tyndale RF, Wilhelmsen K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 2005;15: 115-25. (Pubitemid 40562988)
30. Swan GE, Benowitz NL, Jacob P III, Lessov CN, Tyndale RF, Wilhelmsen K, et al. Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Res 2004;7:435-48. (Pubitemid 39390138)
31. Benowitz NL, Jacob P III, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268:296-303. (Pubitemid 24039102)
32. Benowitz NL, Dains KM, Dempsey D, Havel C, Wilson M, Jacob P III. Urine menthol as a biomarker of mentholated cigarette smoking. Cancer Epidemiol Biomarkers Prev 2010;19:3013-9.
33. Hecht SS. Tobacco carcinogens, their biomarkers and tobaccoinduced cancer. Nat Rev Cancer 2003;3:733-44. (Pubitemid 37328812)
34. Church TR, Anderson KE, Caporaso NE, Geisser MS, Le CT, Zhang Y, et al. A prospectively measured serum biomarker for a tobaccospecific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev 2009;18:260-6.
35. Kamangar F, Strickland PT, Pourshams A, Malekzadeh R, Boffetta P, Roth MJ, et al. High exposure to polycyclic aromatic hydrocarbons may contribute to high risk of esophageal cancer in northeastern Iran. Anticancer Res 2005;25:425-8. (Pubitemid 40470045)
36. Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther 2009;85:635-43.
37. Mwenifumbo JC, Myers MG, Wall TL, Lin SK, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6-7, CYP2A68 and CYP2A6-10 as assessed with a novel haplotyping method. Pharmacogenet Genomics 2005;15:189-92. (Pubitemid 40569906)
38. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006;79: 600-8. (Pubitemid 43817942)
39. Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther 2010;87:553-7.
40. Bernert JT, Alexander JR, Sosnoff CS, McGuffey JE. Time course of nicotine and cotinine incorporation into samples of nonsmokers' beard hair following a single dose of nicotine polacrilex. J Anal Toxicol 2011;35:1-7.
41. Jacob P III, Wilson M, Benowitz NL. Determination of phenolic metabolites of polycyclic aromatic hydrocarbons in human urine as their pentafluorobenzyl ether derivatives using liquid chromatography-tandem mass spectrometry. Anal Chem 2007;79:587-98. (Pubitemid 46110634)
42. Jacob P III, Havel C, Lee DH, Yu L, Eisner MD, Benowitz NL. Subpicogram per milliliter determination of the tobacco-specific carcinogen metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in human urine using liquid chromatography-tandem mass spectrometry. Anal Chem 2008;80:8115-21.
43. Jacob P III, Yu L, Wilson M, Benowitz NL. Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine- 30,30-d2 in humans. Biol Mass Spectrom 1991;20:247-52.
44. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115. (Pubitemid 40283970)
45. Benowitz NL, Kuyt F, Jacob P III, Jones RT, Osman AL. Cotinine disposition and effects. Clin Pharmacol Ther 1983;34:604-11. (Pubitemid 14247719)
46. Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, et al. Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 2007;35:1935-41. (Pubitemid 47481589)
47. Dempsey D, Jacob P III, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 2002;301:594-8. (Pubitemid 34429972)
48. Raunio H, Rautio A, Gullsten H, Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 2001; 52:357-63. (Pubitemid 32939440)
49. Al Koudsi N, Tyndale RF. Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica 2010;40:381-92.
50. Haberl M, Anwald B, Klein K, Weil R, Fuss C, Gepdiremen A, et al. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 2005;15:609-24. (Pubitemid 41113334)